Items Tagged ‘NET’

March 1st, 2017

Xermelo-new option for controlling symptoms of Carcinoid Syndrome

By

The US Food and Drug Administration (FDA) today approved the oral therapy Xermelo (telotristat ethyl) to be used in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea. Carcinoid syndrome is a cluster of symptoms that occurs in patients with advanced neuroendocrine tumors (NET) and the related diarrhea results […]

View full entry

Tags: carcinoid syndrome, General, NET, neuroendocrine tumors, News, Other News Topics (not Types of Cancer), Xermelo


August 10th, 2015

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

By

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients treated with Afinitor plus best supportive care appear to live longer without cancer progression than patients […]

View full entry

Tags: afinitor, everolimus, Gastric Cancer, General Lung Cancer, Lung Cancer, mtor, NET, neuroendocrine tumors, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer